Markus A. Seeliger

6.0k citations

74 papers · 4.5k indexed · 2 hit papers · h-index 33

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 16
- Chronic Myeloid Leukemia Treatments 16
Genetics 10
- Chronic Lymphocytic Leukemia Research 7

Co-authors: John Kuriyan Yibing Shan David E. Shaw Michael P. Eastwood Ron O. Dror Eric T. Kim Nathanael S. Gray Mohammad Azam
Journals: ACS Chemical Biology (6 papers)Journal of Molecular Biology (6 papers)Nature Communications (5 papers)Journal of Biological Chemistry (5 papers)Biochemistry (4 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Markus A. Seeliger

74 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Structural mechanism of a drug-binding process involving a large conformational change of the protein target 2023 · 59 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Communications
2011 Journal of the American Chemical Society

Peers

Countries citing papers authored by Markus A. Seeliger

Since Specialization

Citations

This map shows the geographic impact of Markus A. Seeliger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus A. Seeliger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus A. Seeliger more than expected).

Fields of papers citing papers by Markus A. Seeliger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus A. Seeliger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus A. Seeliger. The network helps show where Markus A. Seeliger may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus A. Seeliger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus A. Seeliger Line = papers co-authored together Markus A. Seeliger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Resistance to Allosteric Inhibitors Journal of Molecular Biology ·Jason R. Birk, Rick Lovering, Sam Chew Chin, Neil P. Shah, İvet Bahar, Markus A. Seeliger	2025	1
2	Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments Current Opinion in Structural Biology ·Ji Young Lee, Hong Chang Woo, Markus A. Seeliger, İvet Bahar	2024	6
3	Calculating Protein–Ligand Residence Times through State Predictive Information Bottleneck Based Enhanced Sampling Journal of Chemical Theory and Computation ·S Irizawa, Dedi Wang, Markus A. Seeliger, Pratyush Tiwary	2024	8
4	Inhibiting p38α MAPK signaling: A balancing act in treating inflammation Journal of Pharmacology and Experimental Therapeutics ·Rick Lovering, Karim Raafat, Markus A. Seeliger	2024	1
5	SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis Nature Communications ·Surbhi Chouhan, Shiva Zarei, Cody Weimholt, Jingqin Luo, Tiandao Li, Myles C. Hodgson, Luana Novaes Santos, TRACY P. COTTER, Bin Fang, John M. Koomen, Markus A. Seeliger, Cheng‐Kui Qu, Armelle Yart, Maria Kontaridis, Kiran Mahajan, Nupam P. Mahajan	2024	7
6	Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting eLife ·Jason R. Birk, Sukrit Singh, Benedict‐Tilman Berger, Stefan Knapp, John D. Chodera, Markus A. Seeliger	2023	3
7	Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance Nature Communications ·Shiva Zarei, Surbhi Chouhan, Kiran Mahajan, Arun Renganathan, Cody Weimholt, Siyabonga Shoba, Melissa A. Reimers, Eric H. Kim, Manish Thakur, Muhammad A. Saeed, Russell K. Pachynski, Markus A. Seeliger, W. Todd Miller, Felix Y. Feng, Nupam P. Mahajan	2022	36
8	Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance Proceedings of the National Academy of Sciences ·Agatha Lyczek, Benedict‐Tilman Berger, 杨敏福, Ping Li, 紳八郎鹿野, 敦山根, H. G. Munshi, Steven K. Albanese, Matthew B. Robers, Stefan Knapp, John D. Chodera, Markus A. Seeliger	2021	40
9	How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture ACS Chemical Biology ·Linglan Fang, N.T. Allcott, Sujata Chakraborty, Zachary E. Potter, Ames C. Register, Markus A. Seeliger, Dustin J. Maly	2020	18
10	Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme Nature Chemical Biology ·Juan Pablo Maianti, A Idoo, Amedeo Vetere, Amagon Kennedy, Bridget K. Wagner, Markus A. Seeliger, David R. Liu	2019	31
11	An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression Biochemistry ·Steven K. Albanese, Daniel L. Parton, Mehtap Işık, Abdul Harits Iftikar Nasution, Sonya M. Hanson, Julie M. Behr, Scott Gradia, Chris Jeans, Nicholas M. Levinson, Markus A. Seeliger, John D. Chodera	2018	35
12	Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods Methods in enzymology on CD-ROM/Methods in enzymology ·Philip F. Uzor, Simone Smecca, Markus A. Seeliger, Michael A. Frohman	2016	7
13	Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles Cell chemical biology ·I. Aaro, George P. Georghiou, Ralph E. Kleiner, Kip E. Guja, Barbara P. Craddock, Agatha Lyczek, Alix I Chan, Miguel Garcı́a-Dı́az, W. Todd Miller, David R. Liu, Markus A. Seeliger	2016	14
14	Fibronectin Interaction and Enhancement of Growth Factors: Importance for Wound Healing Advances in Wound Care ·Katarzyna M. Sawicka, Markus A. Seeliger, Friederike Maechler, Lauren K. Macri, Richard A.F. Clark	2015	62
15	A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis Blood ·S. Leah Etheridge, Ichiro Kumano, Veena Sangkhae, Lana Corbo, Michelle E. Roh, Markus A. Seeliger, Edward K. L. Chan, Ian S. Hitchcock	2013	58
16	Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations Cancer Research ·Markus A. Seeliger, Pratistha Ranjitkar, Corynn Kasap, Yibing Shan, David E. Shaw, Neil P. Shah, John Kuriyan, Dustin J. Maly	2009	127
17	N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor Journal of Biological Chemistry ·Yongmun Choi, Markus A. Seeliger, Shoghag Panjarian, Hak‐Joong Kim, Xianming Deng, Taebo Sim, Brian A. Couch, Anthony J. Koleske, Thomas E. Smithgall, Nathanael S. Gray	2009	45
18	A conserved protonation-dependent switch controls drug binding in the Abl kinase Proceedings of the National Academy of Sciences ·Yibing Shan, Markus A. Seeliger, Michael P. Eastwood, Filipp Frank, Huafeng Xu, Morten Ø. Jensen, Ron O. Dror, John Kuriyan, David E. Shaw	2008	216
19	Structural Basis for the Recognition of c-Src by Its Inactivator Csk Cell ·Nicholas M. Levinson, Markus A. Seeliger, Philip A. Cole, John Kuriyan	2008	103
20	c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty Structure ·Markus A. Seeliger, Bhushan Nagar, Filipp Frank, R.L. Breckinridge, Max Henderson, John Kuriyan	2007	181

About Markus A. Seeliger

Markus A. Seeliger is a scholar working on Hematology, Genetics, Molecular Biology, Rheumatology and Cell Biology, having authored 74 papers that have together received 4.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (16 papers), Protein Kinase Regulation and GTPase Signaling (14 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Protein Structure and Dynamics (11 papers), Eosinophilic Disorders and Syndromes (10 papers), Computational Drug Discovery Methods (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Hematology (760 citations), Genetics (513 citations), Molecular Biology (3.1k citations), Computational Theory and Mathematics (650 citations) and Cell Biology (654 citations). Markus A. Seeliger has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include John Kuriyan, Yibing Shan, David E. Shaw, Michael P. Eastwood, Ron O. Dror, Eric T. Kim, Nathanael S. Gray, Mohammad Azam, George Q. Daley and Michael Tong. Their work appears in journals such as ACS Chemical Biology, Journal of Molecular Biology, Nature Communications, Journal of Biological Chemistry and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact